Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.

ABSTRACT:

Background

The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown.

Objectives

This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF perpetuation.

Methods

The authors conducted a randomized controlled study in 34 sheep that were atrially tachypaced (13 ± 1 week). They compared daily oral EPL (n = 19) versus sugar pill (SP) treatment (n = 15) from the start of tachypacing. The endpoint was a continuous 7-day stretch of persistent AF (n = 29) or completion of 23 weeks tachypacing (n = 5).

Results

EPL significantly reduced the rate of left atrial dilat

SUBMITTER: Takemoto Y 

PROVIDER: S-EPMC5726581 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature